{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:08:35Z","timestamp":1780747715776,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00280-017-3374-x","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T07:21:13Z","timestamp":1498720873000},"page":"371-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Does \u201cOPTINAB\u201d strategy (\u201cstop-and-go\u201d) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel\u2013gemcitabine?"],"prefix":"10.1007","volume":"80","author":[{"given":"Valerie","family":"Relias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Wasif","family":"Saif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,29]]},"reference":[{"key":"3374_CR1","unstructured":"https:\/\/seer.cancer.gov\/archive\/csr\/1975_2013\/results_figure\/sect_01_intro1_6pgs.pdf\n                        \n                    . Accessed 27 June 2017"},{"issue":"6","key":"3374_CR2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris III","year":"1997","unstructured":"Burris HA III, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as the first line therapy for patients with advanced pancreas cancer; a randomized trial. J Clin Oncol 15(6):2403\u20132413","journal-title":"J Clin Oncol"},{"issue":"15","key":"3374_CR3","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960\u20131966","journal-title":"J Clin Oncol"},{"issue":"19","key":"3374_CR4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825","journal-title":"N Engl J Med"},{"issue":"34","key":"3374_CR5","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Hoff Von","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol 29(34):4548\u20134554","journal-title":"J Clin Oncol"},{"issue":"18","key":"3374_CR6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Gabriela Chiorean E, Infante J et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703","journal-title":"N Engl J Med"},{"issue":"2","key":"3374_CR7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/jnci\/dju413","volume":"107","author":"D Goldstein","year":"2015","unstructured":"Goldstein D, Hassan El-Maraghi R, Hammel P, Heinemann V et al (2015) Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long term survival from a phase III trial. J Natl Cancer Inst 107(2):110","journal-title":"J Natl Cancer Inst"},{"key":"3374_CR8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer\u2014a GERCOR study. J Clin Oncol 24:394\u2013400","journal-title":"J Clin Oncol"},{"issue":"5","key":"3374_CR9","first-page":"658","volume":"9","author":"MW Saif","year":"2008","unstructured":"Saif MW (2008) Does OPTIMOX strategy (\u201cstop-and-go\u201d approach) also work in treatment of pancreatic cancer with oxaliplatin-based regimens? JOP 9(5):658\u2013663","journal-title":"JOP"},{"issue":"15","key":"3374_CR10","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","volume":"63","author":"CCCP Verstappen","year":"2003","unstructured":"Verstappen CCCP, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer. Drugs 63(15):1549\u20131563","journal-title":"Drugs"},{"issue":"4","key":"3374_CR11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-2004-861536","volume":"24","author":"EJ Dropcho","year":"2004","unstructured":"Dropcho EJ (2004) Neurotoxicity of cancer chemotherapy. Semin Neurol 24(4):419\u2013426","journal-title":"Semin Neurol"},{"key":"3374_CR12","first-page":"2927","volume":"30","author":"MW Saif","year":"2010","unstructured":"Saif MW, Syrigos K, Kaley K, Isufi I (2010) Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res 30:2927\u20132934","journal-title":"Anticancer Res"},{"key":"3374_CR13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.blre.2014.09.012","volume":"29","author":"RS Magge","year":"2015","unstructured":"Magge RS, DeAngelis LM (2015) The double- edged sword: neurotoxicity of chemotherapy. Blood Rev 29:93\u2013100","journal-title":"Blood Rev"},{"key":"3374_CR14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/jnci\/85.8.676","volume":"85","author":"A Martoni","year":"1993","unstructured":"Martoni A, Zamagni C, Gheka A et al (1993) Antihistamines in the treatment of taxol-induced paroxystic pain syndrome. J Natl Cancer Inst 85:676","journal-title":"J Natl Cancer Inst"},{"issue":"suppl_2","key":"3374_CR15","doi-asserted-by":"publisher","first-page":"ii83","DOI":"10.1093\/annonc\/mdw199.276","volume":"27","author":"P Vincent","year":"2016","unstructured":"Vincent P et al (2016) P-286Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1\/2 study. Ann Oncol 27(suppl_2):ii83\u2013ii84. doi:\n                        10.1093\/annonc\/mdw199.276","journal-title":"Ann Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3374-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T10:29:42Z","timestamp":1501151382000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3374-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,29]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3374"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3374-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,29]]}}}